Eli Lilly: If at First You Don't Succeed...

Each week, we like to take a moment to boil down the biggest news from the most influential companies in the pharmaceuticals industry, and tell our viewers what that news means for you. We call that segment our Big Pharma Roundup.

In this week's installment, Merck gave us an update on its Alzheimer's program last week, and now, Eli Lilly has given an update on its Alzheimer's drug solanezumab. The company plans to conduct further phase 3 trials for patients with a milder form of the disease, despite failures with the drug in other phase 3 trials, as the data suggests there may be some benefit for those patients.

Over the next two years, Eli Lilly will see nearly $0.40 of every $1.00 in sales exposed to generic competition. How does the company plan to respond to this huge patent cliff? Better yet, what does this mean for investors? In a brand new premium report on Eli Lilly, The Motley Fool's top pharmaceuticals analyst delves into everything investors need to know about the stock today. Simply click here now to claim your copy.

The article Eli Lilly: If at First You Don't Succeed... originally appeared on Fool.com.

Brenton Flynn has no positions in the stocks mentioned above. The Motley Fool owns shares of Johnson & Johnson. Motley Fool newsletter services recommend Elan and Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.